Body Mass Index in Multiple Sclerosis: Associations with CSF Neurotransmitter Metabolite Levels.

ISRN Neurology Pub Date : 2013-09-24 eCollection Date: 2013-01-01 DOI:10.1155/2013/981070
Manolis Markianos, Maria-Eleftheria Evangelopoulos, Georgios Koutsis, Panagiota Davaki, Constantinos Sfagos
{"title":"Body Mass Index in Multiple Sclerosis: Associations with CSF Neurotransmitter Metabolite Levels.","authors":"Manolis Markianos,&nbsp;Maria-Eleftheria Evangelopoulos,&nbsp;Georgios Koutsis,&nbsp;Panagiota Davaki,&nbsp;Constantinos Sfagos","doi":"10.1155/2013/981070","DOIUrl":null,"url":null,"abstract":"<p><p>Body weight and height of patients with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome suggesting MS (CIS) in the age range 18 to 60 years (154 males and 315 females) were compared with those of subjects (146 males and 212 females) free of any major neurological disease. In drug-free patients, CSF levels of the metabolites of noradrenaline (MHPG), serotonin (5-HIAA), and dopamine (HVA), neurotransmitters involved in eating behavior, were estimated in searching for associations with body mass index (BMI). Statistical evaluations were done separately for males and females. Lower BMI was found in female MS patients compared to female controls, more pronounced in RRMS. BMI was not associated with duration of illness, smoking, present or previous drug treatment, or disability score. Body height showed a shift towards greater values in MS patients compared to controls. Patients in the lower BMI quartile (limits defined from control subjects) had lower 5-HIAA and HVA compared to patients in the upper quartile. The results provide evidence for weight reduction during disease process in MS, possibly related to deficits in serotoninergic and dopaminergic activities that develop during disease course, resulting in impairments in food reward capacity and in motivation to eat. </p>","PeriodicalId":14626,"journal":{"name":"ISRN Neurology","volume":"2013 ","pages":"981070"},"PeriodicalIF":0.0000,"publicationDate":"2013-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/981070","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ISRN Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2013/981070","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 22

Abstract

Body weight and height of patients with relapsing-remitting multiple sclerosis (RRMS) or clinically isolated syndrome suggesting MS (CIS) in the age range 18 to 60 years (154 males and 315 females) were compared with those of subjects (146 males and 212 females) free of any major neurological disease. In drug-free patients, CSF levels of the metabolites of noradrenaline (MHPG), serotonin (5-HIAA), and dopamine (HVA), neurotransmitters involved in eating behavior, were estimated in searching for associations with body mass index (BMI). Statistical evaluations were done separately for males and females. Lower BMI was found in female MS patients compared to female controls, more pronounced in RRMS. BMI was not associated with duration of illness, smoking, present or previous drug treatment, or disability score. Body height showed a shift towards greater values in MS patients compared to controls. Patients in the lower BMI quartile (limits defined from control subjects) had lower 5-HIAA and HVA compared to patients in the upper quartile. The results provide evidence for weight reduction during disease process in MS, possibly related to deficits in serotoninergic and dopaminergic activities that develop during disease course, resulting in impairments in food reward capacity and in motivation to eat.

多发性硬化症的体重指数:与脑脊液神经递质代谢物水平的关系。
将年龄在18至60岁的复发-缓解型多发性硬化症(RRMS)或临床孤立综合征提示多发性硬化症(CIS)患者(154名男性和315名女性)的体重和身高与无任何主要神经系统疾病的受试者(146名男性和212名女性)的体重和身高进行比较。在无药物患者中,为了寻找与体重指数(BMI)的关联,研究人员估计了与饮食行为有关的神经递质去甲肾上腺素(MHPG)、血清素(5-HIAA)和多巴胺(HVA)的脑脊液代谢物水平。统计评估分别对男性和女性进行。与女性对照组相比,女性多发性硬化症患者的BMI较低,在RRMS中更为明显。BMI与疾病持续时间、吸烟、目前或以前的药物治疗或残疾评分无关。与对照组相比,多发性硬化症患者的身高变化更大。BMI较低四分位数的患者(从对照组定义的限制)与较高四分位数的患者相比,其5-HIAA和HVA较低。该结果为MS患者在疾病过程中体重减轻提供了证据,可能与疾病过程中出现的血清素和多巴胺活性缺陷有关,导致食物奖励能力和进食动机受损。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信